MedTrace Logo

Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid

NCT05297123 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-28

No results posted yet for this study

Summary

The clinical trial was designed to prove that Arsenic plus ATRA possibly had an effect on improving the symptoms, reducing the early mortality rate and prolonging the total survival time of patients with newly diagnosed or relapsed AML.

Conditions

Interventions

DRUG

All-trans retinoic acid

All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.

DRUG

Arsenic Trioxide

ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)

DRUG

Realgar-Indigo naturalis formula

60 mg/kg/d for 8 weeks

Sponsors & Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University

    lead OTHER

Principal Investigators

  • Huaiyu Wang, Dr. · First Affiliated Hospital Xi'an Jiaotong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-03
Primary Completion
2023-12-03
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05297123 on ClinicalTrials.gov